Jazz Pharmaceuticals PLC (JAZZ)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 48.77% | 48.26% | 43.16% | 42.19% | 39.76% | 37.06% | 38.44% | 33.32% | 34.07% | 48.46% | 62.04% | 81.11% | 93.06% | 93.41% | 93.65% | 93.35% | 93.01% | 92.90% | 92.92% | 92.68% |
| Operating profit margin | 15.19% | 5.18% | 1.22% | -0.74% | -1.84% | 7.12% | 7.44% | 3.00% | 5.68% | 10.28% | 17.58% | 29.96% | 16.01% | 11.67% | 9.16% | 9.56% | 24.66% | 31.96% | 35.85% | 33.82% |
| Pretax margin | 7.74% | -2.87% | -7.30% | -9.03% | -10.72% | -2.59% | -2.91% | -7.87% | -3.79% | 2.74% | 12.05% | 25.49% | 11.52% | 7.35% | 5.11% | 5.80% | 20.85% | 28.02% | 31.76% | 29.50% |
| Net profit margin | 10.89% | 2.15% | -2.35% | -4.27% | -6.28% | -0.54% | -1.54% | -14.08% | -10.99% | -5.62% | 1.53% | 21.27% | 10.10% | 7.87% | 6.02% | 12.83% | 24.25% | 29.65% | 33.03% | 24.89% |
Jazz Pharmaceuticals plc has demonstrated strong profitability over the quarters, as evidenced by consistently high gross profit margins ranging from 84.37% to 88.64%. The operating profit margin has also shown a stable increasing trend, ranging from 2.90% to 15.59%. However, the pretax margin and net profit margin have had more variability, with pretax margins fluctuating from -10.46% to 7.69% and net profit margins ranging from -13.63% to 10.82%.
Overall, Jazz Pharmaceuticals plc has generally managed to maintain healthy profitability ratios, with the latest quarter showing the highest profitability across all measured margins. The company's ability to continuously improve operating efficiency and maintain high gross margins is a positive indicator of its financial performance. Nonetheless, the fluctuations in pretax and net profit margins suggest some variability in operational performance and effectiveness in managing operating expenses and tax liabilities. Monitoring these ratios over time can provide insights into the company's profitability trends and operational effectiveness.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 5.08% | 1.72% | 0.40% | -0.24% | -0.60% | 2.38% | 2.24% | 0.81% | 1.38% | 2.36% | 3.50% | 10.80% | 5.78% | 4.23% | 3.34% | 4.01% | 9.61% | 11.87% | 12.97% | 12.51% |
| Return on assets (ROA) | 3.64% | 0.71% | -0.77% | -1.41% | -2.07% | -0.18% | -0.46% | -3.82% | -2.68% | -1.29% | 0.30% | 7.67% | 3.65% | 2.85% | 2.20% | 5.38% | 9.45% | 11.01% | 11.95% | 9.21% |
| Return on total capital | 6.54% | 2.24% | 0.49% | -0.30% | -0.75% | 2.93% | 2.73% | 1.00% | 1.71% | 2.89% | 4.35% | 12.92% | 6.86% | 5.09% | 3.89% | 4.76% | 11.36% | 14.19% | 15.64% | 15.38% |
| Return on equity (ROE) | 11.10% | 2.29% | -2.45% | -4.69% | -7.26% | -0.68% | -1.62% | -12.47% | -8.31% | -4.09% | 0.97% | 13.65% | 6.52% | 5.31% | 4.24% | 9.98% | 16.82% | 19.93% | 21.98% | 17.81% |
1. Operating return on assets (Operating ROA) has been relatively stable and positive over the quarters, ranging from 4.33% to 5.24%. This indicates that Jazz Pharmaceuticals has been efficient in generating operating income from its assets.
2. Return on assets (ROA) has shown significant fluctuations, varying from -3.82% to 3.64%. While the company experienced negative ROA in some quarters, it generally improved over time, which could suggest better asset utilization and profitability.
3. Return on total capital has consistently remained positive, with a range of 0.90% to 6.29%. This metric reflects the company's ability to generate returns for both equity and debt holders over the quarters.
4. Return on equity (ROE) has also shown variability, from -12.47% to 11.10%. Despite the fluctuations, Jazz Pharmaceuticals managed to achieve positive ROE in the last few quarters, indicating a return on shareholder equity investment.
Overall, the profitability ratios demonstrate Jazz Pharmaceuticals' ability to effectively utilize its assets and capital to generate profits, with improvements in ROA and ROE over time. However, the company should continue monitoring its performance to ensure sustainable profitability.